Serial #79386026 Trademark
Serial Number: 79386026 • Registration: 7484222
Serial #79386026 is a trademark filed by
MERCK KGaA
on November 23, 2023. The trademark is classified under Class 5 (Pharmaceuticals).
The application is currently registered and active.
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
William C. Wright Epstein Drangel LLP
60 East 42nd Street, Suite 1250
New York, NY 10165
United States
Trademark Details
Filing Date
November 23, 2023
Registration Date
August 27, 2024
Published for Opposition
June 11, 2024
Goods & Services
Pharmaceutical preparations for use in oncology
Filing History
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 6, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 20, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 20, 2025 OPNR
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 8, 2025 FINV
FINAL DISPOSITION NOTICE SENT TO IB
Feb 15, 2025 FICS
FINAL DISPOSITION PROCESSED
Feb 15, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 29, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 27, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 27, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 11, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 11, 2024 PUBO
REFUSAL PROCESSED BY IB
May 22, 2024 RFNT
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 22, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 3, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 3, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 3, 2024 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 27, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 27, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 10, 2024 RFCR
NON-FINAL ACTION WRITTEN
Apr 9, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 2, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 2, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 27, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 21, 2023 REPR
